Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes

Journal of Cancer Research and Clinical Oncology

Volumn 143, Issue 9, 2017, Pages 1833-1844

  Rottmann, Miriam ^a   Burges, A ^a   Mahner, S ^a   Anthuber, C ^b   Beck, T ^c   Grab, D ^d   Schnelzer, A ^e   Kiechle, M ^e   Mayr, D ^a   Polcher M ^f   Schubert Fritschle, G ^a   Engel, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Klinikum Starnberg   (Germany)

^c RoMed Clinical Centre Rosenheim   (Germany)

^d Klinikum Harlaching   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Red Cross Hospital   (Germany)

Author keywords

Cancer registry; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prognostic factors; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL OUTCOME; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT; PERITONEUM CANCER; PRIORITY JOURNAL; SURVIVAL ANALYSIS; UTERINE TUBE CARCINOMA; VERY ELDERLY; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UTERINE TUBE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 85018360433     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-017-2422-6     Document Type: Article

References (30)

1. Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A (2016) FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol. doi:10.1016/j.ygyno.2016.06.013
2. Bamias A et al (2012) Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer (Oxford, England: 1990) 48:1476–1483. doi:10.1016/j.ejca.2011.09.023
3. Berek JS, Crum C, Friedlander M (2015) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 131(Suppl 2):S111–S122. doi:10.1016/j.ijgo.2015.06.007
4. Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C (2011) Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer 105:1818–1824. doi:10.1038/bjc.2011.455
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259
6. Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493–498. doi:10.1016/j.ygyno.2013.05.040
7. Chene G, Dauplat J, Radosevic-Robin N, Cayre A, Penault-Llorca F (2013) Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis. Crit Rev Oncol Hematol 88:134–143. doi:10.1016/j.critrevonc.2013.03.004
8. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244. doi:10.1002/cncr.24149
9. Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological Note No. 10. End Results Evaluation Section. National Cancer Institute
10. Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi:10.1002/ijc.29210
11. Gao B et al (2016) Serous ovarian and primary peritoneal cancers: a comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecol Oncol 142:458–464. doi:10.1016/j.ygyno.2016.06.023
12. Gershenson DM et al (2015) Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol 33:2675–2682. doi:10.1200/jco.2015.61.0873
13. Gibson SJ, Fleming GF, Temkin SM, Chase DM (2016) The application and outcome of standard of care treatment in elderly women with ovarian cancer: a literature review over the last 10 years. Front Oncol 6:63. doi:10.3389/fonc.2016.00063
14. Grabowski JP et al (2016) Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 140:457–462. doi:10.1016/j.ygyno.2016.01.022
15. Kalbfleisch J, Prentice R (1980) The statistical analysis of failure time data. Wiley, New York
16. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA (2016) Low-grade serous ovarian cancer: a review. Gynecol Oncol. doi:10.1016/j.ygyno.2016.08.320
17. Kleppe M, van der Aa MA, Van Gorp T, Slangen BF, Kruitwagen RF (2016) The impact of lymph node dissection and adjuvant chemotherapy on survival: a nationwide cohort study of patients with clinical early-stage ovarian cancer. Eur J Cancer (Oxford, England: 1990) 66:83–90. doi:10.1016/j.ejca.2016.07.015
18. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumour of female reproductive organs, 4th edn. International Agency for Research on Cancer, Lyon
19. Munich Cancer Registry (2016) Catchment area of MCR. http://www.tumorregister-muenchen.de/en/area.php. Accessed 4 Oct 2016
20. Rauh-Hain JA et al (2015) Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol 212:600.e601–608. doi:10.1016/j.ajog.2014.12.013
21. Robert Koch Institute (RKI) (2014) Cancer in Germany 2009/2010, 9th edn. German Centre for Cancer Registry Data (ZfKD). http://www.krebsdaten.de/Krebs/EN. Accessed 5 Oct 2016
22. Sant M et al (2015) Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer (Oxford, England: 1990). doi:10.1016/j.ejca.2015.07.022
23. Schnack TH, Sorensen RD, Nedergaard L, Hogdall C (2014) Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology—a prospective comparative study. Gynecol Oncol 135:278–284. doi:10.1016/j.ygyno.2014.08.020
24. Seidman JD, Zhao P, Yemelyanova A (2011) “Primary peritoneal” high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 120:470–473. doi:10.1016/j.ygyno.2010.11.020
25. Sobin L, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumours. International union against cancer (UICC), 7th edn. Wiley-Liss, New York
26. Sorensen RD, Schnack TH, Karlsen MA, Hogdall CK (2015) Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities—a systematic review. Gynecol Oncol 136:571–581. doi:10.1016/j.ygyno.2015.01.534
27. Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS, Chan JK (2015) Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol 212:188.e181–186. doi:10.1016/j.ajog.2014.08.016
28. Wethington SL et al (2008) Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 113:3298–3306. doi:10.1002/cncr.23957
29. Winter WE 3rd et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627. doi:10.1200/jco.2006.10.2517
30. Woopen H, Inci G, Richter R, Chekerov R, Ismaeel F, Sehouli J (2016) Elderly ovarian cancer patients: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). Eur J Cancer (Oxford, England: 1990) 60:101–106. doi:10.1016/j.ejca.2016.03.008